Evidence map›Paper›PMID 41362921›Full record

ArticleGut microbes2025

Antagonistic drug interactions protect commensal

Patrick Müller, Verena Schmidtchen, Jacobo de la Cuesta-Zuluaga, Lucía Pérez Jiménez, Cordula Gekeler, André Mateus, Lisa Maier

Abstract read
In one paragraph

Article in Gut microbes, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Patrick MüllerInterfaculty Institute for Microbiology and Infection Medicine Tübingen, University of Tübingen, Tübingen, Germany.ORCID 0000-0003-3290-8251
Verena SchmidtchenInterfaculty Institute for Microbiology and Infection Medicine Tübingen, University of Tübingen, Tübingen, Germany.ORCID 0009-0009-2740-9950
Jacobo de la Cuesta-ZuluagaInterfaculty Institute for Microbiology and Infection Medicine Tübingen, University of Tübingen, Tübingen, Germany.ORCID 0000-0002-7369-992X
Lucía Pérez JiménezDepartment of Chemistry, Umeå University, Umeå, Sweden.ORCID 0000-0002-1302-7494
Cordula GekelerInterfaculty Institute for Microbiology and Infection Medicine Tübingen, University of Tübingen, Tübingen, Germany.ORCID 0000-0001-9041-6672
André MateusDepartment of Chemistry, Umeå University, Umeå, Sweden.ORCID 0000-0001-6870-0677
Lisa MaierInterfaculty Institute for Microbiology and Infection Medicine Tübingen, University of Tübingen, Tübingen, Germany.ORCID 0000-0002-6473-4762

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Antibiotics are essential to modern medicine, but their broad-spectrum activity can unintentionally disrupt the gut microbiota. This collateral damage may be alleviated by antagonistic drug interactions, in which specific compounds used in combination therapies selectively protect beneficial gut microbes from antibiotic activity. Using efflux pump inhibitors, transcriptomic and proteomic analyses, and targeted gene deletions, we show that a variety of non-antibiotic pharmaceuticals-from diverse therapeutic classes and at sub-inhibitory concentrations-can protect multiple

Indexed as

Anti-Bacterial AgentsBacterial ProteinsBacteroidetesMacrolidesMembrane Transport ProteinsDrug InteractionsDrug Resistance, BacterialGastrointestinal MicrobiomeAnti-Bacterial AgentsBacterial ProteinsMacrolidesMembrane Transport ProteinsantagonismBacteroidaceaeefflux pumpsnon-antibiotic drugs

Identifiers

PMID41362921
PMCPMC12694919

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.